Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Glenn J Lesser

Showing results (111-120 of 127) with videos related to

Pageof 13
Sort By:
Neuro-Oncology|April 5, 2013
Phase 2 study of dose-intense temozolomide in recurrent glioblastomaAndrew D Norden, Glenn J Lesser, Jan Drappatz, et al.
The Oncologist|June 9, 2021
Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain MetastasesRichard S P Huang, James Haberberger, Kimberly McGregor, et al.
NEJM Evidence|March 13, 2023
Statins and Left Ventricular Ejection Fraction Following Doxorubicin TreatmentW Gregory Hundley, Ralph D'Agostino, Teresa Crotts, et al.
Neuro-Oncology|October 11, 2017
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02Evanthia Galanis, S Keith Anderson, C Ryan Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2019
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with GlioblastomaPatrick Y Wen, David A Reardon, Terri S Armstrong, et al.
Journal of Neuro-Oncology|October 23, 2014
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomasAndrew D Norden, David Schiff, Manmeet S Ahluwalia, et al.
Oncotarget|October 13, 2025
Treatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fieldsHugo Jimenez, Denise Gibo, Sambad Sharma, et al.
Neurology|December 21, 2014
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningiomaAndrew D Norden, Keith L Ligon, Samantha N Hammond, et al.
International Journal of Radiation Oncology, Biology, Physics|April 7, 2020
Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424Barbara J Fisher, Stephanie L Pugh, David R Macdonald, et al.
Neuro-Oncology|January 25, 2020
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patientsEudocia Q Lee, Michael Weller, Joohee Sul, et al.
Pageof 13

Showing results (111-120 of 127) with videos related to

Sort By:
Pageof 13
Neuro-Oncology|April 5, 2013
Phase 2 study of dose-intense temozolomide in recurrent glioblastomaAndrew D Norden, Glenn J Lesser, Jan Drappatz, et al.
The Oncologist|June 9, 2021
Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain MetastasesRichard S P Huang, James Haberberger, Kimberly McGregor, et al.
NEJM Evidence|March 13, 2023
Statins and Left Ventricular Ejection Fraction Following Doxorubicin TreatmentW Gregory Hundley, Ralph D'Agostino, Teresa Crotts, et al.
Neuro-Oncology|October 11, 2017
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02Evanthia Galanis, S Keith Anderson, C Ryan Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2019
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with GlioblastomaPatrick Y Wen, David A Reardon, Terri S Armstrong, et al.
Journal of Neuro-Oncology|October 23, 2014
Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomasAndrew D Norden, David Schiff, Manmeet S Ahluwalia, et al.
Oncotarget|October 13, 2025
Treatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fieldsHugo Jimenez, Denise Gibo, Sambad Sharma, et al.
Neurology|December 21, 2014
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningiomaAndrew D Norden, Keith L Ligon, Samantha N Hammond, et al.
International Journal of Radiation Oncology, Biology, Physics|April 7, 2020
Phase 2 Study of a Temozolomide-Based Chemoradiation Therapy Regimen for High-Risk, Low-Grade Gliomas: Long-Term Results of Radiation Therapy Oncology Group 0424Barbara J Fisher, Stephanie L Pugh, David R Macdonald, et al.
Neuro-Oncology|January 25, 2020
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patientsEudocia Q Lee, Michael Weller, Joohee Sul, et al.
Pageof 13